EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Mitigation of Ferroptosis in Diabetic Kidney Disease Through Mesenchymal Stem Cell Intervention via the Smad2/3/ METTL3 / S1PR1 Axis

Li-Lan Huang, Yue-Yuan Hou, Ji Yang, Xing-Na Liao, Jin-Sha Ma, Wen-Chao Wang, Yi-Xiao Quan, Hong-Ying Jiang, Yi-Hua Bai iD

The FASEB Journal · 2025

DOI: 10.1096/fj.202403207r ↗

Kurz gefasst

Fachartikel in der Zeitschrift The FASEB Journal, 2025. Verfasst von Li-Lan Huang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, The Second Hospital Affiliated to Kunming Medical University, Kunming, China. Hauptthemen laut MEDLINE: Ferroptosis, Diabetic Nephropathies, Mesenchymal Stem Cells, Methyltransferases. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Yunnan Revitalization Talent Support Program, Reserve Talents Project for Young and Middle-aged Academic and Technical Leaders in Yunnan Province, Yunnan Fundamental Research Kunming Medical University Joint Projects.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diabetic kidney disease (DKD) is a leading cause of end‐stage renal disease (ESRD) and is associated with heightened cardiovascular risk and increased overall mortality. Although mesenchymal stem cells (MSCs) have demonstrated therapeutic potential in DKD, their precise mechanisms of action have not been fully elucidated. This study aimed to investigate the involvement of Smad signaling, N6‐methyladenosine (m6A) modifications, and ferroptosis in MSC‐mediated treatment of DKD. Cellular and animal models of DKD were used to evaluate MSC intervention effects, supported by gene knockdown and overexpression experiments. Protein expression and phosphorylation levels of Smad2/3, m6A‐associated enzymes, and markers of ferroptosis were assessed. Additionally, transcriptional targets associated with ferroptosis were identified through integrated transcriptome and m6A methylation sequencing analyses, followed by subsequent validation. Elevated Smad2/3 phosphorylation and ferroptosis were observed in DKD, while MSC interventions effectively alleviated these processes, resulting in improved renal lesions. Furthermore, MSC treatment reduced the heightened levels of m6A modification observed in DKD. Mechanistic investigations identified methyltransferase‐like 3 (METTL3) as a key regulator of m6A modification in DKD. Suppression of METTL3 reversed the upregulated m6A modification and ferroptosis induced by Smad2 overexpression. Importantly, sphingosine‐1‐phosphate receptor 1 ( S1PR1 ) was identified as a protective target gene against ferroptosis in DKD. In DKD models, Smad2 facilitated the m6A modification of the S1PR1 gene by interacting with METTL3 following its nuclear translocation, thereby influencing S1PR1 expression and promoting cellular ferroptosis. Intervention with MSCs mitigated this process, providing further insights into the regulatory mechanisms through which MSCs modulate ferroptosis in podocytes affected by DKD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FerroptosisDiabetic NephropathiesMesenchymal Stem CellsMethyltransferasesSmad2 ProteinSphingosine-1-Phosphate ReceptorsSmad3 ProteinMesenchymal Stem Cell TransplantationAnimalsHumansMiceSignal TransductionMaleMice, Inbred C57BL

Stichwörter der Autor:innen

S1PR1METTL3Smadsdiabetic kidney diseaseferroptosishuman umbilical cord mesenchymal stem cells

Substanzen

MethyltransferasesSmad2 ProteinSphingosine-1-Phosphate ReceptorsSmad3 ProteinMETTL3 protein, humanSMAD2 protein, humanSMAD3 protein, human

Autor:innen und Institutionen

  • Department of Nephrology, The Second Hospital Affiliated to Kunming Medical University, Kunming, China.

ORCID-Profile: Yi-Hua Bai

Förderung

  • Yunnan Revitalization Talent Support Program
  • Reserve Talents Project for Young and Middle-aged Academic and Technical Leaders in Yunnan Province
  • Yunnan Fundamental Research Kunming Medical University Joint Projects
  • Kunming Medical University Innovation Fund for Postgraduates in 2024
  • The Second Affiliated Hospital of Kunming Medical University Talent Echelon Cultivation Project-Academic Leader
  • National Clinical Research Center of Chronic Kidney Disease, the Second Affiliated Hospital of Kunming Medical University

Zitieren

APA

Huang, L. L., Hou, Y. Y., Yang, J., Liao, X. N., Ma, J. S., Wang, W. C., Quan, Y. X., Jiang, H. Y., & Bai, Y. H. (2025). Mitigation of Ferroptosis in Diabetic Kidney Disease Through Mesenchymal Stem Cell Intervention via the Smad2/3/ METTL3 / S1PR1 Axis. The FASEB Journal. https://doi.org/10.1096/fj.202403207r

Vancouver

Huang LL, Hou YY, Yang J, Liao XN, Ma JS, Wang WC, et al. Mitigation of Ferroptosis in Diabetic Kidney Disease Through Mesenchymal Stem Cell Intervention via the Smad2/3/ METTL3 / S1PR1 Axis. The FASEB Journal. 2025. doi:10.1096/fj.202403207r

BibTeX
@article{Huang2025,
  author = {Huang, Li-Lan and Hou, Yue-Yuan and Yang, Ji and Liao, Xing-Na and Ma, Jin-Sha and Wang, Wen-Chao and Quan, Yi-Xiao and Jiang, Hong-Ying and Bai, Yi-Hua},
  title = {Mitigation of Ferroptosis in Diabetic Kidney Disease Through Mesenchymal Stem Cell Intervention via the Smad2/3/ METTL3 / S1PR1 Axis},
  journal = {The FASEB Journal},
  year = {2025},
  doi = {10.1096/fj.202403207r}
}
Kostenlos starten →